A re-assessment of the role of combined androgen blockade for advanced prostate cancer.
about
Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancerHormone therapy in combination with radiotherapy in the treatment of prostate cancer: why and in which group of patients?Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients.Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cellsAndrogens as therapy for androgen receptor-positive castration-resistant prostate cancer.Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic reviewCombination hormonal therapy: a reassessment within advanced prostate cancer.Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.Goserelin acetate in combination with radiotherapy for prostate cancer.Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: a retrospective clinical experience from a Chinese medical centre.Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer.Case study: management of advanced prostate cancer with soft tissue metastases.Feasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and dexamethasone for docetaxel-refractory prostate cancer.Use of combined androgen blockade for advanced prostate cancer in British Columbia.Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade.Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition).Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers.Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL.A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancerNumber-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials
P2860
Q26747782-ED86F58C-4316-4AD7-B6C6-8E519547E4C1Q26801132-2381BD81-9578-4FC7-82C1-8654A713A26FQ34596863-23EEF06C-D054-4A9C-B80D-ED8F393829A9Q35070404-7A50BF0C-8297-4315-A34C-8997EB8870DBQ35207110-907B55A3-51AC-4419-8222-DD21732DC8E2Q35840364-358CD308-F7B8-4925-87C5-E6882B06E93CQ35886568-1E4AA59A-37ED-4E65-8CB3-B258456DE653Q36381291-19A4825B-1A56-43CD-B56E-2A2C73AD7391Q36719711-3997A1C3-38D5-4CBA-A942-E4F220DADCE1Q37084596-40EE55EF-1F97-4F72-95E5-21679C9F87CFQ38803264-9539815A-6A1F-48C5-B46D-D93983027C26Q43427594-B5930BF6-5DBC-4B15-9354-0F7C81B4A66CQ46531728-1B0F39F8-7197-4FAE-91CE-4088CFBE4E06Q47103953-157945BB-86F1-441E-BD23-638EB07522CBQ51133487-52F2DB0B-6AFC-4F82-84FC-B9F11965E8FCQ52647560-5B986153-2E5C-4D9B-9F8B-DA99A35E59D3Q53488049-7F53C6A1-867F-4E94-A560-48FFE242675FQ53734447-8671DC2B-6370-483F-B8A1-A6450890DAC8Q54301350-B7E2E815-BE10-4BFD-A3F0-ED1A25B5C7E8Q55068843-39455972-8364-4118-B17B-918D9C0822E1Q57109413-583E519F-4774-4664-9C4A-3C1F338BA3C7Q58761734-47905139-8589-474F-8201-7A1C900E7F26
P2860
A re-assessment of the role of combined androgen blockade for advanced prostate cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
A re-assessment of the role of combined androgen blockade for advanced prostate cancer.
@ast
A re-assessment of the role of combined androgen blockade for advanced prostate cancer.
@en
type
label
A re-assessment of the role of combined androgen blockade for advanced prostate cancer.
@ast
A re-assessment of the role of combined androgen blockade for advanced prostate cancer.
@en
prefLabel
A re-assessment of the role of combined androgen blockade for advanced prostate cancer.
@ast
A re-assessment of the role of combined androgen blockade for advanced prostate cancer.
@en
P2093
P2860
P1433
P1476
A re-assessment of the role of combined androgen blockade for advanced prostate cancer.
@en
P2093
Schellhammer P
P2860
P304
P356
10.1111/J.1464-410X.2004.04803.X
P577
2004-06-01T00:00:00Z